2. Esophageal Adenocarcinoma

  1. Janusz Jankowski MB ChB, MSc, MD, PhD, FRCP, FACG, AGAF1,2,3 and
  2. Ernest Hawk MD, MPH4

Published Online: 15 NOV 2012

DOI: 10.1002/9781118423318.ch2

Handbook of Gastrointestinal Cancer

Handbook of Gastrointestinal Cancer

How to Cite

Jankowski, J. and Hawk, E. (eds) (2012) Esophageal Adenocarcinoma, in Handbook of Gastrointestinal Cancer, John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9781118423318.ch2

Editor Information

  1. 1

    Sir James Black Professor of Gastrointestinal Biology and Trials, Centre for Digestive Diseases, Barts and Th e London School of Medicine and Dentistry, London, UK

  2. 2

    Consultant Gastroenterologist, University Hospitals of Leicester, Leicester, UK

  3. 3

    James Black Senior Fellow, University of Oxford, Oxford, UK

  4. 4

    Vice President and Division Head, Division of Cancer Prevention & Population Sciences, Boone Pickens Distinguished Chair for Early Prevention of Cancer, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Publication History

  1. Published Online: 15 NOV 2012
  2. Published Print: 12 JUL 2012

ISBN Information

Print ISBN: 9780470656242

Online ISBN: 9781118423318



  • Barrett's esophagus;
  • esophageal adenocarcinoma;
  • aspirin;
  • genome;
  • biomarkers;
  • epidemiology;
  • obesity;
  • metaplasia;
  • endoscopy;
  • cancer


Barrett's esophagus and the related esophageal adenocarcinoma have increased throughout developed and developing countries. Obese patients with benign Barrett's esophagus with frequent reflux symptoms who are older than 50 years are much likely to have dysplasia or cancer.

While predisposition to Barrett's adenocarcinoma seems polygenic, Tylosis that predisposes to esophageal squamous cancer has recently been shown to be associated with specific RHBDF2 mutations.

Genetic screening for Barrett's is still in the research environment but data from two consortia EAGLE (United Kingdom and Dutch) and BEACON (a dispersed worldwide population), each with 5,000 patients, should provide important data on inherited factors. Furthermore, the role of chemoprevention using acid suppression and or aspirin is being tested in the AspECT trial.